论文部分内容阅读
目的通过高致病性人禽流感H5N1全病毒-MF59佐剂疫苗滴鼻免疫Balb/c小鼠,评价该疫苗所诱导的系统免疫与黏膜免疫应答效果。方法以不同剂量抗原按比例与MF59佐剂配伍制成粘膜疫苗,滴鼻免疫Balb/c小鼠,二免2周采血检测血清IgG、IgM效价及血清中HAI(HAinhibitor)的中和抗体效价,同时收集鼻、肺灌洗液,检测其IgG和sIgA抗体效价。结果H5N1+MF59组血清抗体效价较H5N1组有显著升高(P<0.01);在各剂量组中,随着剂量的增加抗体效价呈上升趋势,12μg后抗体效价呈下降趋势,以H5N1+MF59(12μg)组效价最高;肺鼻灌洗液中,均可检测到特异性分泌型IgA、IgG,其中特异性分泌型IgA效价略高于IgG;抗体亚型的分布以IgG1、IgG2b为主。结论灭活高致病性禽流感全病毒H5N1在佐剂MF59作用下可诱导机体产生体液免疫应答,同时还可以在黏膜局部产生特异性分泌型IgA、IgG,为高致病人禽流感病毒H5N1黏膜疫苗的研制奠定了基础。
Objective To immunize Balb / c mice with the HPAI-FM59 adjuvant vaccine of the highly pathogenic human bird flu to evaluate the systemic and mucosal immune responses induced by the vaccine. Methods BALB / c mice were immunized intranasally with different doses of antigen in combination with MF59 adjuvant. Serum IgG, IgM titer and serum HAI (HAinhibitor) neutralizing antibody Price, while collecting nasal and pulmonary lavage fluid, testing its IgG and sIgA antibody titers. Results The titer of serum antibody of H5N1 + MF59 group was significantly higher than that of H5N1 group (P <0.01). In each dose group, the titer of antibody increased with the increase of dose, and the titer of antibody decreased after 12μg H5N1 + MF59 (12μg) group had the highest titer; specific secreted IgA and IgG were detected in the lung-nasal lavage fluid, and the specific secretory IgA titer was slightly higher than that of IgG; the distribution of antibody subtypes was IgG1 , IgG2b based. Conclusions The inactivated HPAI H5N1 can induce humoral immune response in the body of adjuvant MF59. In addition, specific secreted IgA and IgG can be produced locally in the mucosa, which are highly pathogenic H5N1 Mucosal vaccine laid the foundation for the development.